APO Research
Talk to an analyst

APO RESEARCH · REPORT

Meningococcal Group B Vaccine

Compare research editions
View pricing & licenses

Selected research

Industry Research

Meningococcal Group B Vaccine Industry Research Report 2026

22 December 2025112 pages

Choose your research edition.

Industry ResearchMeningococcal Group B Vaccine Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Meningococcal Group B Vaccine Industry Growth and Trends Forecast to 203279 pages · $3,450 USDMarket StructureGlobal Meningococcal Group B Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032175 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Meningococcal Group B Vaccine Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Meningococcal Group B Vaccine Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Meningococcal Group B Vaccine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Meningococcal Group B Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Meningococcal Group B Vaccine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Meningococcal Group B Vaccine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Meningococcal Group B Vaccine include GSK and Pfizer among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Meningococcal Group B Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Meningococcal Group B Vaccine Market by Company

GSK

Pfizer

Meningococcal Group B Vaccine Segment by Type

Bexsero

Trumenba

Other

Meningococcal Group B Vaccine Segment by Application

Public

Private

Meningococcal Group B Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Meningococcal Group B Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Meningococcal Group B Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Meningococcal Group B Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Meningococcal Group B Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Meningococcal Group B Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Meningococcal Group B Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Meningococcal Group B Vaccine Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Meningococcal Group B Vaccine Sales (k units) of Manufacturers (2021-2026) Table 7. Global Meningococcal Group B Vaccine Sales Market Share by Manufacturers (2021-2026) Table 8. Global Meningococcal Group B Vaccine Revenue of Manufacturers (2021-2026) Table 9. Global Meningococcal Group B Vaccine Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Meningococcal Group B Vaccine Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Meningococcal Group B Vaccine Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Meningococcal Group B Vaccine, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Meningococcal Group B Vaccine, Product Type & Application Table 14. Global Meningococcal Group B Vaccine Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Meningococcal Group B Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. GSK Company Information Table 19. GSK Business Overview Table 20. GSK Meningococcal Group B Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. GSK Meningococcal Group B Vaccine Product Portfolio Table 22. GSK Recent Developments Table 23. Pfizer Company Information Table 24. Pfizer Business Overview Table 25. Pfizer Meningococcal Group B Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Pfizer Meningococcal Group B Vaccine Product Portfolio Table 27. Pfizer Recent Developments Table 28. Global Meningococcal Group B Vaccine Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 29. Global Meningococcal Group B Vaccine Sales by Region (2021-2026) & (k units) Table 30. Global Meningococcal Group B Vaccine Sales Market Share by Region (2021-2026) Table 31. Global Meningococcal Group B Vaccine Sales by Region (2027-2032) & (k units) Table 32. Global Meningococcal Group B Vaccine Sales Market Share by Region (2027-2032) Table 33. Global Meningococcal Group B Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 34. Global Meningococcal Group B Vaccine Revenue Market Share by Region (2021-2026) Table 35. Global Meningococcal Group B Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 36. Global Meningococcal Group B Vaccine Revenue Market Share by Region (2027-2032) Table 37. North America Meningococcal Group B Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. North America Meningococcal Group B Vaccine Sales by Country (2021-2026) & (k units) Table 39. North America Meningococcal Group B Vaccine Sales by Country (2027-2032) & (k units) Table 40. North America Meningococcal Group B Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 41. North America Meningococcal Group B Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 42. Europe Meningococcal Group B Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 43. Europe Meningococcal Group B Vaccine Sales by Country (2021-2026) & (k units) Table 44. Europe Meningococcal Group B Vaccine Sales by Country (2027-2032) & (k units) Table 45. Europe Meningococcal Group B Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 46. Europe Meningococcal Group B Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 47. Asia Pacific Meningococcal Group B Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Asia Pacific Meningococcal Group B Vaccine Sales by Country (2021-2026) & (k units) Table 49. Asia Pacific Meningococcal Group B Vaccine Sales by Country (2027-2032) & (k units) Table 50. Asia Pacific Meningococcal Group B Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 51. Asia Pacific Meningococcal Group B Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 52. South America Meningococcal Group B Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 53. South America Meningococcal Group B Vaccine Sales by Country (2021-2026) & (k units) Table 54. South America Meningococcal Group B Vaccine Sales by Country (2027-2032) & (k units) Table 55. South America Meningococcal Group B Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 56. South America Meningococcal Group B Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 57. Middle East and Africa Meningococcal Group B Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Middle East and Africa Meningococcal Group B Vaccine Sales by Country (2021-2026) & (k units) Table 59. Middle East and Africa Meningococcal Group B Vaccine Sales by Country (2027-2032) & (k units) Table 60. Middle East and Africa Meningococcal Group B Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 61. Middle East and Africa Meningococcal Group B Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 62. Global Meningococcal Group B Vaccine Sales by Type (2021-2026) & (k units) Table 63. Global Meningococcal Group B Vaccine Sales by Type (2027-2032) & (k units) Table 64. Global Meningococcal Group B Vaccine Sales Market Share by Type (2021-2026) Table 65. Global Meningococcal Group B Vaccine Sales Market Share by Type (2027-2032) Table 66. Global Meningococcal Group B Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 67. Global Meningococcal Group B Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 68. Global Meningococcal Group B Vaccine Revenue Market Share by Type (2021-2026) Table 69. Global Meningococcal Group B Vaccine Revenue Market Share by Type (2027-2032) Table 70. Global Meningococcal Group B Vaccine Price by Type (2021-2026) & (US$/unit) Table 71. Global Meningococcal Group B Vaccine Price by Type (2027-2032) & (US$/unit) Table 72. Global Meningococcal Group B Vaccine Sales by Application (2021-2026) & (k units) Table 73. Global Meningococcal Group B Vaccine Sales by Application (2027-2032) & (k units) Table 74. Global Meningococcal Group B Vaccine Sales Market Share by Application (2021-2026) Table 75. Global Meningococcal Group B Vaccine Sales Market Share by Application (2027-2032) Table 76. Global Meningococcal Group B Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 77. Global Meningococcal Group B Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 78. Global Meningococcal Group B Vaccine Revenue Market Share by Application (2021-2026) Table 79. Global Meningococcal Group B Vaccine Revenue Market Share by Application (2027-2032) Table 80. Global Meningococcal Group B Vaccine Price by Application (2021-2026) & (US$/unit) Table 81. Global Meningococcal Group B Vaccine Price by Application (2027-2032) & (US$/unit) Table 82. Key Raw Materials Table 83. Raw Materials Key Suppliers Table 84. Meningococcal Group B Vaccine Distributors List Table 85. Meningococcal Group B Vaccine Customers List Table 86. Meningococcal Group B Vaccine Industry Trends Table 87. Meningococcal Group B Vaccine Industry Drivers Table 88. Meningococcal Group B Vaccine Industry Restraints Table 89. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Meningococcal Group B Vaccine Product Image Figure 5. Global Meningococcal Group B Vaccine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Meningococcal Group B Vaccine Market Size (2021-2032) & (US$ Million) Figure 7. Global Meningococcal Group B Vaccine Sales (2021-2032) & (k units) Figure 8. Global Meningococcal Group B Vaccine Average Price (US$/unit) & (2021-2032) Figure 9. Bexsero Product Image Figure 10. Trumenba Product Image Figure 11. Other Product Image Figure 12. Public Product Image Figure 13. Private Product Image Figure 14. Global Meningococcal Group B Vaccine Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Meningococcal Group B Vaccine, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Meningococcal Group B Vaccine Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Meningococcal Group B Vaccine Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Meningococcal Group B Vaccine Sales by Region in 2025 Figure 20. Global Meningococcal Group B Vaccine Revenue by Region in 2025 Figure 21. North America Meningococcal Group B Vaccine Market Size by Country in 2025 Figure 22. North America Meningococcal Group B Vaccine Sales Market Share by Country (2021-2032) Figure 23. North America Meningococcal Group B Vaccine Revenue Market Share by Country (2021-2032) Figure 24. United States Meningococcal Group B Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Meningococcal Group B Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Mexico Meningococcal Group B Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe Meningococcal Group B Vaccine Market Size by Country in 2025 Figure 28. Europe Meningococcal Group B Vaccine Sales Market Share by Country (2021-2032) Figure 29. Europe Meningococcal Group B Vaccine Revenue Market Share by Country (2021-2032) Figure 30. Germany Meningococcal Group B Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France Meningococcal Group B Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. Meningococcal Group B Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy Meningococcal Group B Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Russia Meningococcal Group B Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Spain Meningococcal Group B Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Meningococcal Group B Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Switzerland Meningococcal Group B Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Sweden Meningococcal Group B Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Poland Meningococcal Group B Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific Meningococcal Group B Vaccine Market Size by Country in 2025 Figure 41. Asia Pacific Meningococcal Group B Vaccine Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific Meningococcal Group B Vaccine Revenue Market Share by Country (2021-2032) Figure 43. China Meningococcal Group B Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan Meningococcal Group B Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea Meningococcal Group B Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India Meningococcal Group B Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia Meningococcal Group B Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Taiwan Meningococcal Group B Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Meningococcal Group B Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Meningococcal Group B Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America Meningococcal Group B Vaccine Market Size by Country in 2025 Figure 52. South America Meningococcal Group B Vaccine Sales Market Share by Country (2021-2032) Figure 53. South America Meningococcal Group B Vaccine Revenue Market Share by Country (2021-2032) Figure 54. Brazil Meningococcal Group B Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina Meningococcal Group B Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Chile Meningococcal Group B Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Middle East and Africa Meningococcal Group B Vaccine Market Size by Country in 2025 Figure 58. Middle East and Africa Meningococcal Group B Vaccine Sales Market Share by Country (2021-2032) Figure 59. Middle East and Africa Meningococcal Group B Vaccine Revenue Market Share by Country (2021-2032) Figure 60. Egypt Meningococcal Group B Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. South Africa Meningococcal Group B Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Israel Meningococcal Group B Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Türkiye Meningococcal Group B Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. GCC Countries Meningococcal Group B Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Global Meningococcal Group B Vaccine Sales Market Share by Type (2021-2032) Figure 66. Global Meningococcal Group B Vaccine Revenue Market Share by Type (2021-2032) Figure 67. Global Meningococcal Group B Vaccine Price (US$/unit) by Type (2021-2032) Figure 68. Global Meningococcal Group B Vaccine Sales Market Share by Application (2021-2032) Figure 69. Global Meningococcal Group B Vaccine Revenue Market Share by Application (2021-2032) Figure 70. Global Meningococcal Group B Vaccine Price (US$/unit) by Application (2021-2032) Figure 71. Meningococcal Group B Vaccine Value Chain Figure 72. Meningococcal Group B Vaccine Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Meningococcal Group B Vaccine Industry Opportunities and Challenges

Scope & coverage.

Types
  • Bexsero
  • Trumenba
  • Other
Applications
  • Public
  • Private
Companies covered
  • GSK
  • Pfizer

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Meningococcal Group B Vaccine Market Size (2021-2032)
  4. 2.2.2 Global Meningococcal Group B Vaccine Sales (2021-2032)
  5. 2.2.3 Global Meningococcal Group B Vaccine Market Average Price (2021-2032)
  6. 2.3 Meningococcal Group B Vaccine by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Bexsero
  9. 2.3.3 Trumenba
  10. 2.3.4 Other
  11. 2.4 Meningococcal Group B Vaccine by Application
  12. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  13. 2.4.2 Public
  14. 2.4.3 Private
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Meningococcal Group B Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Meningococcal Group B Vaccine Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Meningococcal Group B Vaccine Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Meningococcal Group B Vaccine Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Meningococcal Group B Vaccine Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Meningococcal Group B Vaccine, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Meningococcal Group B Vaccine, Product Type & Application
  8. 3.8 Global Manufacturers of Meningococcal Group B Vaccine, Established Date
  9. 3.9 Global Meningococcal Group B Vaccine Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 GSK
  2. 4.1.1 GSK Company Information
  3. 4.1.2 GSK Business Overview
  4. 4.1.3 GSK Meningococcal Group B Vaccine Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 GSK Meningococcal Group B Vaccine Product Portfolio
  6. 4.1.5 GSK Recent Developments
  7. 4.2 Pfizer
  8. 4.2.1 Pfizer Company Information
  9. 4.2.2 Pfizer Business Overview
  10. 4.2.3 Pfizer Meningococcal Group B Vaccine Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Pfizer Meningococcal Group B Vaccine Product Portfolio
  12. 4.2.5 Pfizer Recent Developments
5 Global Meningococcal Group B Vaccine Market Scenario by Region
  1. 5.1 Global Meningococcal Group B Vaccine Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Meningococcal Group B Vaccine Sales by Region: 2021-2032
  3. 5.2.1 Global Meningococcal Group B Vaccine Sales by Region: 2021-2026
  4. 5.2.2 Global Meningococcal Group B Vaccine Sales by Region: 2027-2032
  5. 5.3 Global Meningococcal Group B Vaccine Revenue by Region: 2021-2032
  6. 5.3.1 Global Meningococcal Group B Vaccine Revenue by Region: 2021-2026
  7. 5.3.2 Global Meningococcal Group B Vaccine Revenue by Region: 2027-2032
  8. 5.4 North America Meningococcal Group B Vaccine Market Facts & Figures by Country
  9. 5.4.1 North America Meningococcal Group B Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Meningococcal Group B Vaccine Sales by Country (2021-2032)
  11. 5.4.3 North America Meningococcal Group B Vaccine Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Meningococcal Group B Vaccine Market Facts & Figures by Country
  16. 5.5.1 Europe Meningococcal Group B Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Meningococcal Group B Vaccine Sales by Country (2021-2032)
  18. 5.5.3 Europe Meningococcal Group B Vaccine Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Meningococcal Group B Vaccine Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Meningococcal Group B Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Meningococcal Group B Vaccine Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Meningococcal Group B Vaccine Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Meningococcal Group B Vaccine Market Facts & Figures by Country
  41. 5.7.1 South America Meningococcal Group B Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Meningococcal Group B Vaccine Sales by Country (2021-2032)
  43. 5.7.3 South America Meningococcal Group B Vaccine Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Meningococcal Group B Vaccine Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Meningococcal Group B Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Meningococcal Group B Vaccine Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Meningococcal Group B Vaccine Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Meningococcal Group B Vaccine Sales by Type (2021-2032)
  2. 6.1.1 Global Meningococcal Group B Vaccine Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Meningococcal Group B Vaccine Sales Market Share by Type (2021-2032)
  4. 6.2 Global Meningococcal Group B Vaccine Revenue by Type (2021-2032)
  5. 6.2.1 Global Meningococcal Group B Vaccine Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Meningococcal Group B Vaccine Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Meningococcal Group B Vaccine Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Meningococcal Group B Vaccine Sales by Application (2021-2032)
  2. 7.1.1 Global Meningococcal Group B Vaccine Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Meningococcal Group B Vaccine Sales Market Share by Application (2021-2032)
  4. 7.2 Global Meningococcal Group B Vaccine Revenue by Application (2021-2032)
  5. 7.2.1 Global Meningococcal Group B Vaccine Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Meningococcal Group B Vaccine Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Meningococcal Group B Vaccine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Meningococcal Group B Vaccine Value Chain Analysis
  2. 8.1.1 Meningococcal Group B Vaccine Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Meningococcal Group B Vaccine Production Mode & Process
  5. 8.2 Meningococcal Group B Vaccine Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Meningococcal Group B Vaccine Distributors
  8. 8.2.3 Meningococcal Group B Vaccine Customers
9 Global Meningococcal Group B Vaccine Analyzing Market Dynamics
  1. 9.1 Meningococcal Group B Vaccine Industry Trends
  2. 9.2 Meningococcal Group B Vaccine Industry Drivers
  3. 9.3 Meningococcal Group B Vaccine Industry Opportunities and Challenges
  4. 9.4 Meningococcal Group B Vaccine Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst